Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 20/20 | 1.00 |
| ▸ | ITGB2 | P05107 | 19/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203596 | 1.00 | ITGAL (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL5203942 | 0.89 | ITGAL (0.80) | ITGALITGB2ICAM1 | |
| SCHEMBL5239341 | 0.89 | ITGAL (0.80) | ITGALITGB2ICAM1 | |
| SCHEMBL13879396 | 0.84 | ITGAL (0.73) | ITGALITGB2ICAM1 | |
| SCHEMBL12647778 | 0.83 | ITGAL (0.70) | ITGALITGB2ICAM1 | |
| SCHEMBL6312522 | 0.83 | ITGAL (0.70) | ITGALITGB2ICAM1 | |
| SCHEMBL21688324 | 0.82 | ITGAL (0.69) | ITGALITGB2ICAM1 | |
| SCHEMBL13817247 | 0.77 | ITGB2 (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL13817048 | 0.77 | ITGB2 (0.71) | ITGALITGB2ICAM1 | |
| SCHEMBL4018223 | 0.77 | ITGB2 (1.00) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230384307-A1 | IMPROVED DETECTION OF LYMPHOCYTE - TARGET CELL INTERACTION | LUMICKS CA HOLDING B.V. (NL) | 2023-11-30 | — | — | US | claimed |
| EP-4232199-A1 | END FITTING FOR A PRESSURISED FLUID RESERVOIR | LUMICKS CA Holding B.V. (NL) | 2023-08-30 | — | — | EP | claimed |
| CN-116490279-A | Improved detection of lymphocyte-target cell interactions | 卢米科思CA控股有限公司 | 2023-07-25 | — | — | CN | claimed |
| WO-2022086328-A1 | IMPROVED DETECTION OF LYMPHOCYTE - TARGET CELL INTERACTION | LUMICKS CA HOLDING B.V. (NL) | 2022-04-28 | — | — | WO | claimed |
| EP-4224162-B1 | METHOD FOR MEASURING IMMUNOSTIMULATORY RESPONSE OF IMMUNE CELL, METHOD FOR DETERMINING ABILITY TO FORM IMMUNE SYNAPSE IN IMMUNE CELL, AND CELL ANALYZER | SYSMEX CORP (JP) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025059549-A1 | PATIENT SELECTION FOR IMMUNE CELL THERAPY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024160957-A1 | PROCESS FOR MEASURING CELL-CELL INTERACTIONS | LUMICKS CA HOLDING B.V. (NL) | 2024-08-08 | — | — | WO | disclosed |
| US-11939369-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240010726-A1 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | UNIVERSITÄT BASEL (CH) | 2024-01-11 | — | — | US | disclosed |
| US-20230384307-A1 | IMPROVED DETECTION OF LYMPHOCYTE - TARGET CELL INTERACTION | LUMICKS CA HOLDING B.V. (NL) | 2023-11-30 | — | — | US | disclosed |
| EP-4232199-A1 | END FITTING FOR A PRESSURISED FLUID RESERVOIR | LUMICKS CA Holding B.V. (NL) | 2023-08-30 | — | — | EP | disclosed |
| CN-116507345-A | LFA-1 signaling mediators for cancer therapy | 巴塞尔大学 | 2023-07-28 | — | — | CN | disclosed |
| US-6846643-B2 | Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-20030175814-A1 | Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy | WOSKA JOSEPH R (US) | 2003-09-18 | — | — | US | disclosed |
| EP-1311852-A1 | METHODS AND MOLECULES USEFUL FOR IDENTIFYING MOLECULES THAT BIND LFA-1 AND FOR DETERMINING RECEPTOR OCCUPANCY | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020068305-A1 | Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002024307-A2 | REDUCING THE CONTENT OF PARTICULAR CELL TYPES IN A BIOLOGICAL SAMPLE | ALLIED THERAPEUTICS LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002014865-A1 | METHODS AND MOLECULES USEFUL FOR IDENTIFYING MOLECULES THAT BIND LFA-1 AND FOR DETERMINING RECEPTOR OCCUPANCY | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939369-B2 | Integrin antagonists | ITGB3, ITGA2B, ITGB1 | ITGAL 10/4885ITGB2 4/4885ICAM1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.